Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
$2.63
$10.35M1.58352,864 shs120,938 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$13.78
-4.8%
$12.58
$8.04
$25.88
$373.73M2.27418,793 shs251,217 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.01
-2.9%
$12.65
$5.76
$27.38
$151.21M0.43156,203 shs148,463 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%+5.59%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-2.10%+6.20%+12.25%+49.28%-33.36%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-5.28%-1.24%-1.67%-12.52%+106.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.6893 of 5 stars
3.62.00.00.01.92.50.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3824 of 5 stars
3.50.01.72.73.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00
N/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00
N/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$54.00296.04% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50153.01% Upside

Current Analyst Ratings Breakdown

Latest AGLE, AGRX, ARCT, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$2.33M0.00N/AN/A($60.61) per share0.00
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.98M0.52N/AN/A($5.51) per share-0.27
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$131.27M2.82N/AN/A$8.90 per share1.53
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.76$0.81 per share14.81$2.05 per share5.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$3.65N/AN/A-36.24%N/A-147.37%N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.36N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest AGLE, AGRX, ARCT, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.11N/AN/AN/A$17.64 millionN/A
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$0.715.24%N/AN/A N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.49%N/A26.09%3 Years

Latest AGLE, AGRX, ARCT, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
4.59
4.59
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.56
0.38
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.06
5.64
5.64
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
6.60%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
16.60%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
694.05 million3.78 millionOptionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
306.86 million6.82 millionNot Optionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.62 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage Declares Quarterly Dividend
LifeVantage: Activation Of Shareholder Value
LifeVantage (LFVN) Receives a Buy from Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeglea BioTherapeutics stock logo

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Agile Therapeutics stock logo

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$13.78 -0.70 (-4.83%)
Closing price 04:00 PM Eastern
Extended Trading
$13.78 0.00 (-0.04%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.01 -0.36 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$12.02 +0.01 (+0.04%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.